EUCTR2004-000555-42-DKActive, not recruitingNot Applicable
A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses
Sanofi-aventis US, Inc0 sites1,080 target enrollmentStarted: January 23, 2008Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 1,080
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Subjects meeting all of the following criteria will be considered for enrollment into the study:
- •- MS subjects, aged 18 to 55, who are ambulatory (EDSS less or equal than 5.5)
- •- Exhibiting a relapsing clinical course, with or without progression (Relapsing Remitting, Secondary Progressive or Progressive Relapsing)
- •- Meeting McDonald’s criteria for MS diagnosis
- •- Experienced at least 1 relapse over the 1 year preceding the trial or at least 2 relapses over the 2 years preceding the trial
- •- No relapse onset in the preceding 60 days prior to randomization
- •- During the 4 weeks prior to randomization, subjects must have been clinically stable, without adrenocorticotrophic hormone (ACTH) or systemic steroid treatment
- •- Signed main informed consent form and the informed consent for HIV testing
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •- Subjects with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia
- •- Subjects with a congenital or acquired severe immunodeficiency, a history of cancer (except for basal or squamous cell skin lesions which have been surgically excised, with no evidence of metastasis), lymphoproliferative disease, or any subject who has received lymphoid irradiation
- •- Human immunodeficiency virus (HIV) positive status; known history of active tuberculosis not adequately treated; persistent significant or severe infection
- •- Pregnancy, breastfeeding, subjects wishing to parent children during the course of the trial
- •- Therapies that are disallowed (minimum of 4 weeks prior to randomization): phenytoin, warfarin, tolbutamide, St. John's Wort or cholestyramine
- •- Subjects must not have used ACTH or systemic corticosteroids for 4 weeks prior to randomization
- •- Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or MYCOPHENOLATE;
- •- Prior use of natalizumab (Tysabri)
- •- Prior use of interferons or cytokine therapy in the preceding 4 months; prior use of glatiramer acetate therapy in the preceding 6 months; prior use of intravenous immunoglobulins in the preceding 6 months; prior use of any investigational drug in the preceding 6 months; previous treatment with teriflunomide or leflunomide (ARAVA®)
- •- Contraindication for MRI, i.e., presence of pacemaker, metallic implants in high-risk areas (i.e., artificial heart valves, aneurysm/vessel clips), presence of metallic material (i.e., shrapnel) in high risk areas, known history of allergy to any contrast medium, or history of claustrophobia that would prevent completion of all protocol-scheduled MRI. Hip implants are not contraindicated.
- •- Liver function impairment or persisting elevations of SGPT/ALT, serum glutamic oxaloacetic transaminase (SGOT/AST), or direct bilirubin greater than 1.5-fold the upper limit of normal (ULN);
- •- Persisting elevations of serum amylase or lipase greater than 2-fold the upper limit of normal
- •- Known history of active hepatitis
- •- Hypoproteinemia (e.g., in case of severe liver disease or nephrotic syndrome) with serum albumin <3.0 g/dL
- •- Known history of chronic pancreatic disease or pancreatitis
- •- Moderate to severe impairment of renal function, as shown by serum creatinine >133 µmol/L (or >1.5 mg/dL)
- •- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
- •- Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the subject at risk by participating in the study
- •- History of drug or alcohol abuse
- •- Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- •- Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-weektreatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of surinabant: 2.5, 5 and 10mg/day as an aid to smoking cessation in cigarette smokers - SURSMOKEAid to smoking cessation in cigarette smokersMedDRA version: 8.1Level: LLTClassification code 10057852Term: Nicotine dependenceEUCTR2006-005334-21-BEsanofi-aventis recherche et developpement805
Active, not recruiting
Not Applicable
The effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease with slow gastric emptyingInvestigate the ability of the motilin receptor agonist GSK962040 to improve levodopa pharmacokinetics (PK) by enhancing GE via motilin receptor agonism.MedDRA version: 16.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-004438-32-DEGlaxoSmithKline Research and Development Limited70
Active, not recruiting
Phase 1
A study to evaluate the efficacy of AFQ056 in treating abnormal behaviors showed by adolescents (12-17 year-old) with Fragile X SyndromeFragile X SyndromeMedDRA version: 13.1Level: PTClassification code 10017324Term: Fragile X syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-022638-96-FRovartis Pharma Services AG180
Active, not recruiting
Phase 1
A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptomsEUCTR2005-003788-22-GBBoehringer Ingelheim Limited318
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled, parallel-group, multi-centre, Phase IIb, study to determine the effect of BXL628 in women with detrusor overactivity - BXL628 effect in OABOveractive Bladder (OAB)MedDRA version: 9.1Level: LLTClassification code 10020853Term: Hypertonic bladderEUCTR2007-001214-16-ITBIOXELL SPA234